- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2022
- 419 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Report
- April 2023
- 156 Pages
Global
€4834EUR$5,000USD£4,152GBP
- Report
- April 2023
- 114 Pages
Global
€3384EUR$3,500USD£2,906GBP
- Report
- March 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Brovana is a brand of long-acting beta-agonist (LABA) medication used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it helps to open up the airways in the lungs, making it easier to breathe. Brovana is typically used in combination with other medications, such as inhaled corticosteroids, to provide the best relief from COPD symptoms. It is available in both an inhaler and a solution for nebulization.
The Brovana market is a subset of the larger respiratory drugs market, which includes medications used to treat a variety of respiratory conditions, such as asthma, COPD, and cystic fibrosis. The market is highly competitive, with a number of different companies offering similar products.
Some of the companies in the Brovana market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Sunovion Pharmaceuticals. Show Less Read more